NDAORAL-28TABLET
Approved
Dec 1970
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
DEMULEN 1/50-28 (ethinyl estradiol; ethynodiol diacetate) by Pfizer. Approved for pregnancy. First approved in 1970.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DEMULEN 1/50-28 is an oral contraceptive tablet combining ethinyl estradiol and ethynodiol diacetate, approved in 1970 for pregnancy prevention. It is a combination estrogen-progestin formulation taken in a 28-day cycle regimen. The drug works by suppressing ovulation through hormonal mechanisms.
LOE Approaching
Product is approaching loss of exclusivity with minimal commercial headroom; small team focus likely on transition planning and generic readiness.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (1)
Career Relevance
Working on DEMULEN 1/50-28 offers limited career growth potential given LOE Approaching status and zero linked job openings. Opportunities are primarily in defensive commercial work (sustaining sales, generic transition) and regulatory compliance rather than innovation or expansion.
Brand Manager
Worked on DEMULEN 1/50-28 at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.